<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426685</url>
  </required_header>
  <id_info>
    <org_study_id>1539/31/06</org_study_id>
    <secondary_id>40042/07</secondary_id>
    <nct_id>NCT01426685</nct_id>
  </id_info>
  <brief_title>Prognosis of Type 2 Diabetic Patients</brief_title>
  <acronym>ARTEMIS</acronym>
  <official_title>Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Finnish Funding Agency for Technology and Innovation (TEKES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include 1200 patients with type 2 diabetes and angiographically documented&#xD;
      coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes.&#xD;
      Extensive traditional and novel risk marker tests are performed for the patients and they&#xD;
      will be followed-up for 5 years. Sudden cardiac death is the main outcome measure and various&#xD;
      other endpoints are secondary endpoints. As a substudy, 120 diabetic patients and 120&#xD;
      non-diabetic patients will undergo exercise training with home monitoring to assess the&#xD;
      effects of exercise training on risk profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific aims of the study:&#xD;
&#xD;
        1. To compare several autonomic, electric and metabolic risk markers in a case-control&#xD;
           study between the patients with coronary artery disease with and without type II&#xD;
           diabetes at the time of diagnosis of CAD.&#xD;
&#xD;
        2. To assess the prognostic significance of autonomic markers, electrical markers, coronary&#xD;
           angiographic markers and metabolic markers in predicting the cardiac events among the&#xD;
           CAD patients with and without diabetes&#xD;
&#xD;
        3. To develop and test the feasibility of home-monitoring of biosignals among the type II&#xD;
           diabetic patients with CAD.&#xD;
&#xD;
        4. To further explore the molecular, cellular and genetic factors that predispose diabetics&#xD;
           to cardiovascular diseases.&#xD;
&#xD;
        5. To develop new methods for the early clinical diagnosis of vulnerable subjects&#xD;
           susceptible to the complications of the coronary artery disease in Type 2 diabetes.&#xD;
&#xD;
      5. To assess the effects of controlled exercise training programs to several autonomic,&#xD;
      electrical and metabolic risk markers among the type II diabetic patients with CAD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sudden cardiac death</measure>
    <time_frame>2007-2017 (up to ten years)</time_frame>
    <description>Death occuurring within one hour after onset of symptoms, or within 24 hours when the patient has last seen alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>2007-2017 (up to ten years)</time_frame>
    <description>Sudden and non-sudden cardiac death, stroke mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal cardiovascular event</measure>
    <time_frame>2007-2017 (up to ten years)</time_frame>
    <description>acute coronary event, myocardial infarction, congestive heart failure, or stroke needing hospitalization</description>
  </secondary_outcome>
  <enrollment type="Actual">1880</enrollment>
  <condition>Cardiovascular Risk Assessment</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are stored for analysis of various biomarkers and for extracting DNAs.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1200 diabetic patients with coronary artery disease and 600 non-diabetic patients with&#xD;
        coronary artery disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A total of 1200 patients with CAD and diagnosed type II diabetes and 600 patients with&#xD;
             CAD but without evidence of diabetes will be included in the study. The patients will&#xD;
             be recruited from the consecutive series of patients undergoing coronary angiography&#xD;
             in the division of cardiology of the Oulu University Hospital. First, 600 patients&#xD;
             with diabetes will be collected. Thereafter, 600 matched CAD patients without diabetes&#xD;
             will be recruited. The groups will be matched in terms of following variables:&#xD;
&#xD;
               1. sex (1:1)&#xD;
&#xD;
               2. age (&lt;40 years, 40-50 years, 50-60 years, 60-70 years, 70-80 years)&#xD;
&#xD;
               3. history of recent (&lt;3 months) myocardial infarction (1:1)&#xD;
&#xD;
               4. type of coronary intervention after angiography (1:1 CABG ).&#xD;
&#xD;
          -  Diabetes is defined as fasting plasma glucose levels ≥ 7.0 and/or a 2-h postload value&#xD;
             in the OGTT 11.1 mmol/l according to definition and diagnosis of diabetes mellitus and&#xD;
             intermediate hyperglycemia : report of a WHO/IDF consultation. World Health&#xD;
             Organization (WHO) 2006. -&#xD;
&#xD;
          -  Patients without a diabetes must be normoglycemic defined as plasma glucose levels&#xD;
             &lt;6.1 mmol/l in the fasting state and a 2-h postload value &lt; 7.8 mmol/l in the oral&#xD;
             glucose tolerance test (OGTT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • NYHA class IV despite appropriate treatment of heart failure;&#xD;
&#xD;
               -  Planned ICD implantation;&#xD;
&#xD;
               -  Participation in a competing clinical trial that is not accepted by the Steering&#xD;
                  Committee;&#xD;
&#xD;
               -  Psychologically or physically (due to any other illness) unfit for participation&#xD;
                  in the study according to the opinion of the investigator;&#xD;
&#xD;
               -  Patient compliance doubtful;&#xD;
&#xD;
               -  Patients who are geographically or otherwise inaccessible for follow-up;&#xD;
&#xD;
               -  Pregnancy;&#xD;
&#xD;
               -  Life expectancy &lt; 1 year;&#xD;
&#xD;
               -  end-stage renal failure needing dialysis&#xD;
&#xD;
               -  age &lt; 18 years, or &gt; 80 years&#xD;
&#xD;
               -  permanent pacemaker or implantable cardioverter-defibrillator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki V Huikuri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sudden death</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

